Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Video navigation menu
- How do we manage type 2 diabetes and what are we trying to achieve? 0:25
- Hyperglycemia in type 2 diabetes has multiple causes 4:42
- Oral agents: metformin, sulfonyl ureas, thiazolidinediones, alpha glucosidase inhibitors, DPP-4 inhibitors, SGLT-2 inhibitors 6:15
- Injectable agents: GLP-1 receptor agonists, insulin 19:21
- Other agents with an indication to treat hyperglycemia in T2DM 21:51
- Summary: how to target multiple causes of T2DM simultaneously 22:55
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Clifford J. Bailey, PhD, FRCP, FRCPath is a Professor of Clinical Science at School of Life & Health Sciences, Aston University in Birmingham, UK. His research interest includes the pathogenesis of diabetes mellitus and obesity, and the development of new therapies, with a specifc interest in the pathogenesis and interventional approaches against insulin resistance and discovery and development of agents to treat diabetes and obesity.
This recording was independently developed under auspices of PACE-cme. No external funding was received for the production of this video.